CD38 is a protein found on the surface of tumor cells in MM and certain leukemias. Once attached to the CD38 site, MOR202 attracts natural killer cells that can more easily identify and eradicate the cancer cells.
MOR202 has shown encouraging results given alone, as a monotherapy, and with other therapies such as Revlimid and a proteasome inhibitor.
Other companies are interested in the CD38 area as well. Johnson & Johnson's (JNJ - Get Report) biologics unit Janssen Biotech signed a licensing agreement in August with Genmab A/S worth nearly $1 billion to help develop that company's anti-CD38 biologic. Called daratumumab, the drug candidate recently received breakthrough therapy designation from the U.S. Food and Drug Administration. A Phase 1/2 safety study is ongoing.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts